M

    Mirum Pharmaceuticals Inc (MIRM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $98.05
    +0.59 (+0.61%)

    Market Cap: $5.94B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    41%(12/29)
    Avg Surprise
    -70.34%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.42
    Range$-0.53 - $-0.32
    2 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$-0.70-65.3%
    60d ago$-0.70-65.3%
    30d ago$-0.69-61.4%
    7d ago$-0.69-61.4%
    Current$-0.42
    Revenue Consensus
    $178M
    Range$171M - $182M
    11 analysts
    Dec 31, 2026
    EPS Consensus$-13.61
    Range$-13.61 - $-13.61
    1 analysts
    Revenue Consensus
    $199M
    Range$188M - $208M
    13 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-13.61---
    Sep 26EST
    		-$-0.42---
    Jun 26
    		$-0.80$-0.77-3.90%Miss-566.7%
    Mar 26
    		$-1.08$-0.35-208.57%Miss-260.0%
    Dec 25
    		$-0.12$-0.05-146.91%Miss+75.5%
    Sep 25
    		$0.05N/A+131.25%Beat+116.7%
    Jun 25
    		$-0.12N/A+63.64%Beat+76.9%
    Mar 25
    		$-0.30$-0.27-11.11%Miss+44.4%
    Dec 24
    		$-0.49$-0.25-98.70%Miss+25.8%
    Sep 24
    		$-0.30$-0.45+33.33%Beat+47.4%
    Jun 24
    		$-0.52$-0.46-13.04%Miss+20.0%
    Mar 24
    		$-0.54$-0.30-80.00%Miss+32.5%
    Dec 23
    		$-0.66$-0.24-175.00%Miss+33.3%
    Sep 23
    		$-0.57$-0.81+29.63%Beat+44.1%
    Jun 23
    		$-0.65$-0.79+17.72%Beat+22.6%
    Mar 23
    		$-0.80$-0.97+17.53%Beat+31.6%
    Dec 22
    		$-0.99$-1.02+2.94%Beat+40.4%
    Sep 22
    		$-1.02$-1.08+5.56%Beat+36.3%
    Jun 22
    		$-0.84$-1.06+20.75%Beat+42.1%
    Mar 22
    		$-1.17$-1.38+15.22%Beat+30.4%
    Dec 21
    		$-1.66$0.35-574.29%Miss-16.1%
    Sep 21
    		$-1.60$-1.50-6.67%Miss-86.0%
    Jun 21
    		$-1.45$-1.08-34.26%Miss-55.9%
    Mar 21
    		$-1.68$-0.98-71.43%Miss-95.3%
    Dec 20
    		$-1.43$-0.72-98.61%Miss-81.0%
    Sep 20
    		$-0.86$-0.98+12.24%Beat-2.4%
    Jun 20
    		$-0.93$-0.87-6.90%Miss+82.5%
    Mar 20
    		$-0.86$-0.84-2.38%Miss-44.5%
    Dec 19
    		$-0.79$-0.85+7.06%Beat-
    Sep 19
    		$-0.84$-0.63-33.33%Miss-
    Jun 19
    		$-5.31$-0.57-831.58%Miss-
    Mar 19
    		$-0.60$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-50.28EV/EBITDA341.15x
    Price/FCF-27.17xFCF Yield-3.68%
    Profitability
    Profit Margin-139.20%Operating Margin-14.80%
    ROE-703.00%ROIC-116.00%
    Financial Health
    Debt/Equity-71.97xInterest Coverage-63.85x
    Current Ratio2.86xQuick Ratio2.74x
    Trading Statistics
    Beta0.51Avg Volume683.58K
    52-Week High$130.0052-Week Low$63.23

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$98.51
    SMA 20$99.25
    SMA 50$110.09
    SMA 200$95.48
    EMA 10$98.65
    EMA 20$100.69
    EMA 50$104.24
    EMA 200$95.11

    MACD

    Line: -2.94Signal: -3.33Hist: 0.38

    ADX

    ADX: 32.0+DI: 14.8-DI: 24.9

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down32.0
    PSAR$103.91

    Bollinger Bands

    Upper Band$104.66
    Lower Band$93.84
    %B Position1090%(Upper)
    Band Width0.39

    RSI (14-Day)

    Neutral
    42.0

    Momentum Oscillators

    Stoch %K35.4
    Stoch %D41.1
    Williams %R-68.4
    ROC (10d)-1.8%
    Momentum-1.78
    CCI (20d)-63.8
    MFI (14d)65.3

    Volatility Measures

    ATR (14d)$4.18(4.3%)
    StdDev (20d)2.70
    Hist Vol53.8%(High)

    Volume Flow

    VWAP$97.35
    OBV42.5M
    AD Line18.7M
    CMF (20d)0.060

    Volume Metrics

    Avg Vol (20d)692.7K
    Vol Ratio0.6x
    VWMA (20d)$98.58

    Pivot Points

    R3$103.01
    R2$101.54
    R1$99.50
    Pivot Point$98.02
    S1$95.98
    S2$94.51
    S3$92.47

    Advanced Oscillators

    TSI-18.90
    Ultimate Osc59.4
    KST-123.27

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$176.24M$159.88M$148.93M$133.01M$127.78M$111.58M$99.41M$90.38M$77.88M$69.22M$69.55M$47.73M
    Cost of Revenue$30.35M$28.80M$28.26M$25.54M$23.42M$23.02M$22.78M$20.81M$20.23M$17.83M$25.02M$10.23M
    Gross Profit$145.90M$131.08M$120.67M$107.47M$104.36M$88.57M$76.63M$69.57M$57.65M$51.39M$44.53M$37.50M
    Operating Expenses$188.43M$920.54M$125.23M$104.87M$109.35M$103.75M$100.86M$82.25M$81.88M$77.86M$77.12M$62.65M
    R&D$106.96M$824.21M$51.11M$42.96M$46.07M$46.04M$44.03M$31.71M$32.67M$32.22M$30.93M$26.12M
    SG&A$81.47M$96.33M$74.13M$61.91M$63.29M$57.71M$56.83M$50.55M$49.21M$45.64M$46.18M$36.53M
    Operating Income$-42,537,000$-789,465,000$-4,567,000$2.60M$-4,989,000$-15,183,000$-24,222,000$-12,684,000$-24,232,000$-26,468,000$-32,585,000$-25,148,000
    Interest Income$3.85M$3.40M$3.42M$3.25M$3.03M$3.02M$3.20M$3.47M$3.49M$3.63M$3.77M$4.06M
    Interest Expense$2.62M$3.62M$3.60M$3.61M$3.59M$3.60M$3.58M$3.59M$3.57M$3.58M$3.56M$3.57M
    Income Before Tax$-65,538,000$-789,680,000$-4,963,000$2.64M$-5,459,000$-13,648,000$-24,366,000$-13,888,000$-24,003,000$-24,655,000$-35,434,000$-23,339,000
    Income Tax Expense$1.69M$475,000$767,000$-262,000$402,000$1.03M$-576,000$347,000$635,000$624,000$225,000$249,000
    Net Income$-67,227,000$-790,155,000$-5,730,000$2.90M$-5,861,000$-14,677,000$-23,790,000$-14,235,000$-24,638,000$-25,279,000$-35,659,000$-23,588,000
    EBITDA$-59,177,000$-782,137,000$1.73M$9.50M$1.58M$-6,590,000$-17,519,000$-7,292,000$-17,659,000$-18,633,000$-29,753,000$-20,753,000
    EBIT$-66,771,000$-789,465,000$-4,785,000$3.00M$-4,903,000$-13,075,000$-23,991,000$-13,771,000$-23,920,000$-24,711,000$-35,646,000$-23,826,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about MIRM

    Government Contracts

    Gov Obligations (TTM)
    $1139
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    1
    New Awards (TTM)
    0
    Avg Remaining Term
    N/A

    Top agency: Department of Veterans Affairs at 100.0% of trailing twelve month obligations across 1 agencies

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Mirum Pharmaceuticals (MIRM) Following Rare Disease Growth Narrative Looks Undervalued

    Mirum Pharmaceuticals (MIRM) is considered undervalued despite a recent stock price pullback, with a narrative fair value estimate of $144.15 against a current close of $96.72. The company is gaining attention for its Volixibat candidate in liver cirrhosis therapies, and its rare disease portfolio is expected to drive sustained revenue growth due to an expanding patient population. However, the valuation carries risks related to potential underperformance of Livmarli or pressures on rare disease drug pricing.

    Simply Wall Street•8/25/26•
    Somewhat-Bullish

    H.C. Wainwright Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $140

    H.C. Wainwright has reiterated its Buy rating on Mirum Pharmaceuticals (MIRM.US) and maintained its target price at $140. This indicates the firm's continued confidence in the pharmaceutical company's stock performance.

    Moomoo•8/21/26•
    Bullish

    H.C. Wainwright reiterates Mirum Pharmaceuticals stock rating at buy

    H.C. Wainwright has reiterated a Buy rating and a $140.00 price target for Mirum Pharmaceuticals (NASDAQ:MIRM). The company's stock has seen a 53% gain over the past year, though InvestingPro analysis suggests it may be overvalued relative to its Fair Value despite recent earnings revisions. The article also mentions the FDA approval of Regeneron Pharmaceuticals' garetosmab for fibrodysplasia ossificans progressiva, a condition for which Mirum Pharmaceuticals' products are not directly related.

    Investing.com•8/21/26•
    Somewhat-Bullish

    MIRM5806400 Bond Profile — Key Metrics

    This article provides key metrics for the Mirum Pharmaceuticals, Inc. bond (MIRM5806400), detailing its 4.0% coupon rate and a maturity date of May 1, 2029. It outlines the bond's issue date, outstanding amount, face value, and minimum denomination. The company, Mirum Pharmaceuticals, is introduced as a biopharmaceutical firm focused on therapies for liver diseases.

    TradingView•8/21/26•
    Neutral

    Lisanti Capital Growth LLC Takes Position in Mirum Pharmaceuticals, Inc. $MIRM

    Lisanti Capital Growth LLC has acquired 63,295 shares of Mirum Pharmaceuticals (NASDAQ:MIRM) worth $7.41 million, making it their eighth-largest portfolio holding. Other institutional investors like BlackRock, Janus Henderson, State Street, and Wellington Management have also increased their positions. Despite missing quarterly EPS estimates and significant insider selling, analysts maintain a "Moderate Buy" rating with a consensus price target of $137.33.

    MarketBeat•8/20/26•
    Neutral

    Frequently Asked Questions About MIRM

    Does MIRM pay dividends?
    Mirum Pharmaceuticals Inc (MIRM) does not currently pay a regular dividend.
    What is MIRM's market cap?
    Mirum Pharmaceuticals Inc (MIRM) has a market capitalization of $5.94B with a current stock price of $98.05.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In